🇩🇪 We're heading to Berlin for #ESMO25! Oct 17-21. Stop by booth #4034 to explore our suite of #PrecisionOncology solutions shaping the future of cancer care. 📍DON’T MISS: Oct 20 - podium presentation by Edurne Arriola Aperribay, MD, PhD on #MRD analysis from the LAURA study

💗 "Cancer does not define me, but it is a part of who I am. It is a part of my story. This is Mary 2.0. Now’s my second chance." Meet Mary Royal, who's been using NeXT Personal® for over a year after her breast cancer diagnosis in 2023. Her story shows how ultrasensitive ctDNA

🗓️ October is #BreastCancerAwarenessMonth. This month and every month, we recognize the impact that #BreastCancer has on individuals, families, and communities. 💪 We honor breast cancer survivors and those in the fight against this disease. And we thank all of the healthcare

📢 Sponsor Announcement! 📢 We're thrilled to announce that @PersonalisInc is a gold sponsor for Biomarkers & Precision Medicine UK 2025! Register now: https://t.co/MscpRWv5eO #BIOMUK2025 #OGPREMED #PrecisionMedicine #personalis

📄 Check out this article from @GenomeWeb featuring our CMO and EVP of R&D, Richard Chen, speaking about the interim analysis results from the #NEOADAURA trial (#LungCancer): “The current results confirm that the company's platform can track and monitor neoadjuvant treatment

Our team is excited to be in Boston next week for #WorldCDx! Sept 22-25 🗓️ Join us on September 24th at 8:30 AM for an informative session highlighting NeXT Personal®: “Harnessing the Power of Ultra-Sensitive ctDNA Detection for Molecular Response & Endpoint Across All Phases of

🚨 ICYMI: We're partnering with @YaleCancer on the pivotal CATE clinical trial. 🎯 Using NeXT Personal® to identify the earliest molecular signs of recurrence in patients with HR+/HER2- #BreastCancer ahead of imaging. 💊 Patients testing positive get preemptive elacestrant

We're heading to Boston for the 15th World CB & CDx Summit! Sept 22-25 🗓️ Join industry leaders shaping the future of personalized medicine through cutting-edge clinical studies & regulatory insights. Let's connect! 🤝 Schedule a meeting: https://t.co/sn91k2W1Ab

#WCLC25 | NeoADAURA MRD analysis 🔬 ctDNA-based, tumour-informed MRD assay showed higher sensitivity than single EGFR testing 📉 Baseline MRD was prognostic for EFS 💊 Osimertinib (± CTx) improved MRD clearance vs placebo + CTx ✅ Pre-surgical MRD clearance / MRD-negative status

MRD in Neoadaura Neoadjuvant Osimertinib +/- chemo in resectable EGFRm NSCLC. Baseline MRD was prognostic for EFS. Presurgical MRD clearnace and MRD no detected were associated with MPR, proud to participate in this trial @Hospital_FJD @quironsalud @UAM_Madrid @OncoAlert #WCLC25

🫁 Dr @collin_blakely @UCSFCancer presents MRD analysis from NeoADAURA #WCLC25 🔹 Osimertinib & osimertinib+chemo improved MRD clearance & reduced MRD detection pre-surgery vs. chemo 🔹Pre-surgical MRD clearance & MRD not detected associated with MPR #LCSM #LungCancer @IASLC

According to pre-specified exploratory analysis results from the #NeoADAURA trial presented at #WCLC25, baseline MRD status predicted clinical outcomes and pre-surgical MRD-negativity/clearance was linked to major pathological response. Learn more: https://t.co/bQVCs6gGg7

#WCLC 2025: NeoADAURA - CPNPC E.II a IIIB EGFRmut ➡️ tto. Neoadj: QT+Osi vs. Osi vs. QT. Tx MPR: 26% x 25% x 2% Dados de Dç Residual Molecular (MRD)❗️ N=189 MRD ➕ baseline: dç mais extensa, ⬇️ SLE MRD clearence: 83% x 84% x 58% MPR: 24% pts clearence x 6% sem clearence.

Dr. @Joshua_Reuss discussing oral abstracts at #WCLC25 in early stage NSCLC. CheckMate 816 update - better systemic tx doesn’t rescue an R1 resection but does elevate outcomes even with pneumonectomy. Selection critical here. And on NeoADAURA, critical to study residual disease.

🧬 🩸 Neoadjuvant chemo adds nothing to osimertinib in terms of ctDNA clearance or pathological responses in resectable EGFR mutant lung cancer (neoADAURA trial). In my mind, this somehow conflicts with the results from FLAURA -2 in the metastatic setting, where the addition of

CtDNA MRD presentation today from #NeoADAURA trial demonstrates that: 🔹 ultra sensitive assays can detect higher proportion of pts w/ MRD 🔹 as we know, these assays are prognostic at baseline 🔹 clearance correlates with MPR @IASLC #WCLC25

🚀 Ready for #WCLC25? Visit booth #424 to discover our groundbreaking TRACERx results published in Nature Medicine earlier this year. 📊 Additionally, visit an oral presentation from one of our partners, @AstraZeneca, as they highlight MRD analysis from NeoADAURA: neoadjuvant

🚨 NEW data 🚨 from the landmark NeoADAURA trial (neoadjuvant #LungCancer) shows our NeXT Personal® #MRD test is a powerful tool for lung cancer patients. 🫁 (@AstraZeneca) Key findings to be presented at #WCLC25 on September 7 (Abstract OA02.02) about NeXT Personal from the new

See you in Barcelona at #WCLC25! 🫁 Visit Booth #424 to discover NeXT Personal® - our ultrasensitive MRD detection platform featured in the groundbreaking Lung TRACERx study with Professor @CharlesSwanton. 🧬 Improving early-stage #NSCLC risk stratification through ultra-

🧬 NEW #CervicalCancer study interim results supports potential utility of #ctDNA testing using the #UltraSensitive assay, NeXT Personal®, to help guide treatment decisions in locally advanced cervical cancer (LACC) in the future. Don’t miss this @OncLive interview with Dr.